ストックスクリーナーアプリを入手
6.95
0.29%
0.02
アフターアワーズ：
6.95
前日終値:
$6.93
開ける：
$6.93
24時間の取引高:
754.56K
Relative Volume:
0.59
時価総額：
$704.45M
収益：
-
当期純損益:
$-167.48M
株価収益率:
-3.5641
EPS:
-1.95
ネットキャッシュフロー:
$-197.47M
1週間 パフォーマンス:
+7.25%
1か月 パフォーマンス:
-7.09%
6か月 パフォーマンス:
-48.37%
1年 パフォーマンス:
-46.78%
1日の値動き範囲:
$6.805
$7.015
1週間の範囲:
$6.15
$7.205
52週間の値動き範囲:
$6.08
$16.76
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
名前
Day One Biopharmaceuticals Inc
セクター
電話
650 484-0899
住所
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.95 | 656.83M | 0 | -167.48M | -197.47M | -1.95 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-09 | 繰り返されました | Needham | Buy |
| 2024-08-01 | アップグレード | BofA Securities | Underperform → Buy |
| 2024-04-24 | 繰り返されました | Needham | Buy |
| 2023-04-25 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-02-08 | 開始されました | CapitalOne | Overweight |
| 2023-02-03 | 開始されました | Oppenheimer | Perform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-12-05 | 開始されました | Goldman | Buy |
| 2022-12-01 | 開始されました | BofA Securities | Buy |
すべてを表示
Day One Biopharmaceuticals Inc (DAWN) 最新ニュース
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - Insider Monkey
Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301 - Seeking Alpha
Nuveen Asset Management LLC Lowers Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Millennium Management LLC - Defense World
ProShare Advisors LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,894 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Cetera Investment Advisers Has $400,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
36,685 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by BNP Paribas Financial Markets - Defense World
D. E. Shaw & Co. Inc. Increases Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth - Yahoo Finance
Northern Trust Corp Grows Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day one Biopharmaceuticals officer sells $24,574 in stock By Investing.com - Investing.com Nigeria
Day one Biopharmaceuticals officer sells $24,574 in stock - Investing.com
Day One Biopharmaceuticals Executives Sell Shares to Cover Tax Liabilities - TradingView
Day one biopharmaceuticals highlights OJEMDA revenue growth and pipeline progress in Q1 2025 - MSN
Day One Biopharmaceuticals Insider Lowered Holding By 20% During Last Year - simplywall.st
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stake Decreased by Voya Investment Management LLC - Defense World
Transcript : Day One Biopharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now? - MSN
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
10 Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
Trend Tracker for (DAWN) - news.stocktradersdaily.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down – Here’s What Happened - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Research Analysts Issue Forecasts for DAWN Q2 Earnings - Defense World
Needham & Company LLC Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $27.00 - Defense World
Research Analysts Set Expectations for DAWN Q2 Earnings - Defense World
Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Analysts Issue Forecasts for DAWN Q1 Earnings - Defense World
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Mariner LLC - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 12-Month Low Following Analyst Downgrade - Defense World
Day One Biopharma’s Earnings Call Highlights Growth - TipRanks
Day One Biopharmaceuticals (DAWN) Target Price Adjusted to $26 | DAWN Stock News - GuruFocus
Needham Adjusts Price Target for DAWN to $27, Maintains Buy Rati - GuruFocus
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call Transcript - Insider Monkey
MetLife Investment Management LLC Raises Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals earnings beat by $0.07, revenue fell short of estimates - Investing.com Canada
Day One Biopharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Day One Reports First Quarter 2025 Financial Results and Corporate Progress - GlobeNewswire
Earnings call transcript: Day One Biopharmaceuticals beats Q1 2025 EPS forecast - Investing.com
Day One Biopharmaceuticals Q1 2025 slides: OJEMDA revenue grows 11% amid market challenges - Investing.com Canada
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Day One Biopharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Pr - GuruFocus
Day One Biopharmaceuticals (DAWN) Projected to Post Quarterly Earnings on Tuesday - Defense World
Holdings of Day One Biopharmaceuticals Inc (DAWN) are aligned with the stars - Sete News
Wells Fargo & Company MN Sells 4,744 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals Inc (DAWN) 財務データ
収益
当期純利益
現金流量
EPS
Day One Biopharmaceuticals Inc (DAWN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Dubow Adam | GENERAL COUNSEL |
May 16 '25 |
Sale |
6.26 |
4,552 |
28,486 |
47,136 |
| York Charles N II | COO, CFO AND SECRETARY |
May 16 '25 |
Sale |
6.26 |
4,282 |
26,796 |
265,231 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
May 16 '25 |
Sale |
6.26 |
13,964 |
87,385 |
145,737 |
0.86%
1.24%
大文字化:
|
ボリューム (24 時間):